NASDAQ:ZEAL - ZEALAND PHARMA/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.69 +0.22 (+1.42 %)
(As of 07/18/2018 12:46 PM ET)
Previous Close$15.47
Today's Range$15.69 - $15.69
52-Week Range$12.01 - $20.37
Volume54 shs
Average Volume7,351 shs
Market Capitalization$483.10 million
P/E Ratio-10.60
Dividend YieldN/A
BetaN/A
ZEALAND PHARMA/S logoZealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio11.19
Quick Ratio11.19

Price-To-Earnings

Trailing P/E Ratio-10.60
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.23 million
Price / Sales22.73
Cash FlowN/A
Price / CashN/A
Book Value$2.61 per share
Price / Book6.01

Profitability

EPS (Most Recent Fiscal Year)($1.48)
Net Income$-41,350,000.00
Net Margins-460.98%
Return on Equity-75.66%
Return on Assets-52.78%

Miscellaneous

Employees137
Outstanding Shares30,750,000
Market Cap$483.10

The Truth About Cryptocurrencies

ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

How were ZEALAND PHARMA/S's earnings last quarter?

ZEALAND PHARMA/S (NASDAQ:ZEAL) announced its earnings results on Wednesday, May, 16th. The company reported ($0.49) EPS for the quarter. The company earned $1.79 million during the quarter. ZEALAND PHARMA/S had a negative net margin of 460.98% and a negative return on equity of 75.66%. View ZEALAND PHARMA/S's Earnings History.

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for ZEALAND PHARMA/S.

What price target have analysts set for ZEAL?

4 brokerages have issued 12 month price targets for ZEALAND PHARMA/S's shares. Their predictions range from $26.00 to $28.00. On average, they expect ZEALAND PHARMA/S's share price to reach $27.3333 in the next year. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Ratings for ZEALAND PHARMA/S.

What is the consensus analysts' recommendation for ZEALAND PHARMA/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about ZEALAND PHARMA/S stock?

Here are some recent quotes from research analysts about ZEALAND PHARMA/S stock:
  • 1. According to Zacks Investment Research, "Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. " (3/15/2018)
  • 2. Needham & Company LLC analysts commented, "We recently hosted several meetings with investors and Zealand CEO Britt Jensen. Timelines appear intact for several events over the next 3-4 months, including results from a trial in healthy volunteers evaluating feasibility of once-weekly glepaglutide, presentation of Phase 2 glepaglutide data in Short Bowel Syndrome, initiation of a second Phase 3 dasiglucagon trial for Acute Hypoglycemia, and possibly initiation of a Phase 2/3 trial of dasiglucagon in a single-chamber pump format in Congenital Hyperinsulinism (CHI). Collectively, investors were interested in both glepaglutide and dasiglucagon programs, but individually, were more focused on one or the other. Reiterate BUY. We have not included pump applications of dasiglucagon in our valuation. Progress in the form of a deal with a pump maker and Phase 2/3 trial initiation in CHI would represent an important step forward for the company." (10/16/2017)

Who are some of ZEALAND PHARMA/S's key competitors?

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the folowing people:
  • Ms. Britt Meelby Jensen, CEO & Pres (Age 45)
  • Mr. Mats Peter Blom M.B.A., MBA, Exec. VP & CFO (Age 53)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 65)
  • Mr. Ivan Møller, Sr. VP of Technical Devel. & Operations
  • Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 53)

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an initial public offering on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Has ZEALAND PHARMA/S been receiving favorable news coverage?

News coverage about ZEAL stock has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ZEALAND PHARMA/S earned a daily sentiment score of 0.11 on Accern's scale. They also gave media coverage about the company an impact score of 44.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $15.69.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $483.10 million and generates $21.23 million in revenue each year. The company earns $-41,350,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. ZEALAND PHARMA/S employs 137 workers across the globe.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]


MarketBeat Community Rating for ZEALAND PHARMA/S (NASDAQ ZEAL)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote "Outperform" if you believe ZEAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.